[PCSK9 inhibitor use in high cardiovascular risk patients: an interventionalist's overview on efficacy, current recommendations and factual prescription]

G Ital Cardiol (Rome). 2020 Apr;21(4):264-270. doi: 10.1714/3328.32985.
[Article in Italian]
No abstract available

Publication types

  • Editorial

MeSH terms

  • Atherosclerosis / etiology
  • Atherosclerosis / prevention & control
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control*
  • Dyslipidemias / complications
  • Dyslipidemias / drug therapy
  • Heart Disease Risk Factors
  • Humans
  • Hypolipidemic Agents / administration & dosage
  • Hypolipidemic Agents / pharmacology*
  • PCSK9 Inhibitors*

Substances

  • Hypolipidemic Agents
  • PCSK9 Inhibitors
  • PCSK9 protein, human